Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada.

Receive ACST News and Ratings via Email

Sign-up to receive the latest news and ratings for ACST and its competitors with MarketBeat's FREE daily newsletter.

Profitability

Miscellaneous

Acasti Pharma (CVE:ACST) Frequently Asked Questions

What is Acasti Pharma's stock symbol?

Acasti Pharma trades on the Canadian Venture Exchange (CVE) under the ticker symbol "ACST."

Has Acasti Pharma been receiving favorable news coverage?

Press coverage about ACST stock has been trending very positive recently, according to InfoTrie. The research firm identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Acasti Pharma earned a news sentiment score of 3.2 on InfoTrie's scale. They also gave media stories about the company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

How do I buy shares of Acasti Pharma?

Shares of ACST and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Acasti Pharma's stock price today?

One share of ACST stock can currently be purchased for approximately C$1.39.

MarketBeat Community Rating for Acasti Pharma (CVE ACST)

MarketBeat's community ratings are surveys of what our community members think about Acasti Pharma and other stocks. Vote "Outperform" if you believe ACST will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACST will underperform the S&P 500 over the long term. You may vote once every thirty days.